Literature DB >> 30810165

Close Patient Follow-up Among Patients Receiving Outpatient Parenteral Antimicrobial Therapy.

Danielle L Palms1, Jesse T Jacob1,2.   

Abstract

BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) programs allow patients to receive intravenous treatment in the outpatient setting. We developed a predictive model of 30-day readmission among hospitalized patients discharged on OPAT from 2 academic medical centers with a dedicated OPAT clinic for management.
METHODS: A retrospective medical records review was performed and logistic regression was used to assess OPAT and other outpatient clinic follow-up in conjunction with age, sex, pathogen, diagnosis, discharge medication, planned length of therapy, and Charlson comorbidity score. We hypothesized that at least 1 follow-up visit at the Emory OPAT clinic would reduce the risk for hospital readmission within 30 days.
RESULTS: Among 755 patients, 137 (18%) were readmitted within 30 days. Most patients (73%) received outpatient follow-up care at Emory Healthcare within 30 days of discharge or prior to readmission, including 52% of patients visiting the OPAT clinic. The multivariate logistic regression model indicated that a follow-up OPAT clinic visit was associated with lower readmission compared to those who had no follow-up visit (odds ratio, 0.10 [95% confidence interval, .06-.17]) after adjusting for infection with enterococci, Charlson score, discharge location, and county of residence.
CONCLUSIONS: These results can inform potential interventions to prevent readmissions through OPAT clinic follow-up and to further assess factors associated with successful care transitions from the inpatient to outpatient setting.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  OPAT; follow-up; readmission

Mesh:

Substances:

Year:  2020        PMID: 30810165     DOI: 10.1093/cid/ciz150

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  A Quality Initiative to Improve Postdischarge Care for Patients on Outpatient Parenteral Antimicrobial Therapy.

Authors:  Laura K Certain; Russell J Benefield; Michael Newman; Mingyuan Zhang; Frank O Thomas
Journal:  Open Forum Infect Dis       Date:  2022-04-15       Impact factor: 4.423

2.  Factors associated with successful completion of outpatient parenteral antibiotic therapy in an area with a high prevalence of multidrug-resistant bacteria: 30-day hospital admission and mortality rates.

Authors:  Thais Cristina Garbelini Salles; Santiago Grau Cerrato; Tatiana Fiscina Santana; Eduardo Alexandrino Medeiros
Journal:  PLoS One       Date:  2020-11-18       Impact factor: 3.240

3.  OPAT in Switzerland: single-center experience of a model to treat complicated infections.

Authors:  Andrea Erba; Michelle Beuret; Mary-Louise Daly; Nina Khanna; Michael Osthoff
Journal:  Infection       Date:  2019-12-11       Impact factor: 3.553

4.  Perspectives of Patients on Outpatient Parenteral Antimicrobial Therapy: Experiences and Adherence.

Authors:  Yasir Hamad; Sai Dodda; Allison Frank; Joe Beggs; Christopher Sleckman; Glen Kleinschmidt; Michael A Lane; Yvonne Burnett
Journal:  Open Forum Infect Dis       Date:  2020-06-02       Impact factor: 3.835

5.  Which Patients Discharged to Home-Based Outpatient Parenteral Antimicrobial Therapy Are at High Risk of Adverse Outcomes?

Authors:  Sara C Keller; Nae-Yuh Wang; Alejandra Salinas; Deborah Williams; Jennifer Townsend; Sara E Cosgrove
Journal:  Open Forum Infect Dis       Date:  2020-05-20       Impact factor: 3.835

6.  Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults.

Authors:  Kaylen Brzozowski; Rupak Datta; Joseph Canterino; Maricar Malinis; Manisha Juthani-Mehta
Journal:  Open Forum Infect Dis       Date:  2020-08-26       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.